CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00643318
• Other study ID #: ACCL001.0
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 2006
• Est. completion date: December 2021

Study information

• Verified date: August 2019
• Source: Accuray Incorporated
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the short and long-term outcomes after CyberKnife stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable.

Description:

The objectives of this clinical evaluation are to assess the outcomes of patients who undergo stereotactic radiosurgery (SRS) to treat primary early stage non-small cell lung cancer (NSCLC) in patients (comprising of two cohorts, peripheral and central) who are not candidates for surgical resection because of high operative risks. In particular, the effect of CyberKnife SRS on clinical response rate, local control, progression-free survival, overall survival, dyspnea and QOL (for U.S. sites), and radiological findings over two years after treatment will be evaluated.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: December 2021
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient must be over the age of 18 years

2. Pulmonary nodule with maximum diameter = 5 cm

3. Histological confirmation of primary NSCLC

4. The following stage of NSCLC patients are eligible:

• Stage I: T1 N0 M0 or T2 N0 M0 (Tumor size = 5 cm)

• Stage II: T3 N0 M0 (Chest wall invasion only, Tumor size = 5 cm)

5. ECOG/Zubrod status of 0, 1 or 2

6. Thoracic surgery consultation should be obtained from a Board Certified Thoracic surgeon who in collaboration with a radiation oncologist should determine that the patient is not a surgical candidate.

7. In order to be considered medically inoperable, the patient must meet at least one major criteria or a minimum of 2 minor criteria as described below:

MAJOR CRITERIA:

1. FEV1 < 50% or predicted postoperative FEV1 < 40%

2. DLCO < 50% or predicted postoperative DLCO < 40%

3. Exercise induced maximal exercise oxygen consumption M VO2 < 15 mL/kg/min

4. High-risk cardiac disease: Any one of the following:

• Poor left ventricular function (defined as an ejection fraction of <=20%)

• Unstable coronary syndromes (unstable angina or severe angina Canadian class III or IV).

• Severe valvular disease (critical valvular stenosis),

• Recent myocardial infarction (< 1 month),

• Significant arrhythmia defined by one of the following: High-grade AV block, Symptomatic ventricular arrhythmias in the presence of underlying heart disease, Supraventricular arrhythmias with uncontrolled ventricular rate

MINOR CRITERIA:

1. Age > 75

2. Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40 mm Hg)

3. Oxygen requirement (using the Medicare criteria for home oxygen requirements [i.e., room air oxygen saturation of 88% or less])

4. Resting or exercise arterial pO2 = 55 mm Hg OR SpO2 = 88%.

5. pCO2 > 45 mm Hg

6. Congestive heart failure (any three of the following must be documented: dyspnea, peripheral edema, chest x-ray with interstitial edema or cardiomegaly, rales, or congestion)

7. Moderately depressed left ventricular function (defined as an ejection fraction of 21-40% or less)

8. Severe cerebral (with CVA or recent TIA) or severe peripheral vascular disease

9. Diabetes Mellitus with severe organ damage such as ESRD, Blindness, Vascular disease.

10. Severe end organ damage from other causes resulting in ESRD, cirrhosis of the liver or vascular disease

11. FEV1 51%-60% or predicted postoperative FEV1 41-50%

12. DLCO 51-60% or predicted postoperative DLCO 41-50%

13. Modified Medical Research Council Dyspnea Scale = grade 3

8. Females of child-bearing age must be using a reliable form of birth control.

9. The patient must have a PET-CT scan within 8 weeks of registration.

10. The patient must provide a signed and dated written informed consent PRIOR to registration and prior to undergoing any study-related procedures.

11. The patient must provide written authorization to allow the use and disclosure of their protected health information.

Exclusion Criteria:

1. Excluding the primary cancer targeted for this treatment, the patient has a prior history of cancer (within the last 5 years) or concurrent cancer other than basal cell or squamous skin cancer.

2. Visible endobronchial lesion seen in the trachea, carina, major bronchus, lobar or segmental bronchus on bronchoscopy or microscopic disease detected in the trachea, carina, major bronchus, lobar or segmental bronchus.

3. The patient's weight exceeds the tolerances of the institution's imaging and CyberKnife platform/couch.

4. The patient has received thoracic radiation therapy in the same field as the planned treatment area in the past.

5. The patient has completed chemotherapy within less than 30 days of treatment.

6. T2: Tumor size > 5 cm, T3 tumors (except T3 by virtue of chest wall invasion and = 5 cm), T4 tumors. Presence of N1, N2 or N3 disease per previously described criteria would be excluded.

7. Pancoast tumors would be excluded.

8. Current distant metastatic disease (M1) (preferably biopsy proven).

9. The patient is a female with child-bearing potential who refuses to take a pregnancy test prior to treatment.

10. The patient is pregnant or a female who is nursing an infant.

11. The patient is planning on undergoing systemic therapy within 2 weeks after the last fraction of radiation

12. The patient has an active systemic or pulmonary infection.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Radiation:
• CyberKnife Stereotactic Radiosurgery
Central tumors defined as < 2 cm from carina and < 2 cm from right and left mainstem bronchus and/or < 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy) Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)

Locations

Country	Name	City	State
China	Ruikang Hospital	Nanning	Guangxi
China	Tianjin Medical University Cancer Institution and Hospital	Tianjin
United States	Northwest Community Hospital	Arlington Heights	Illinois
United States	Sinai Hospital of Baltimore	Baltimore	Maryland
United States	Penrose Cancer Center	Colorado Springs	Colorado
United States	Baylor Research Institute	Dallas	Texas
United States	Parkview Cancer Center	Fort Wayne	Indiana
United States	Community Regional Medical Center	Fresno	California
United States	North Florida Radiation Oncology	Gainesville	Florida
United States	St. Luke's Episcopal Hospital	Houston	Texas
United States	Central Baptist Hospital	Lexington	Kentucky
United States	Denver CyberKnife	Lone Tree	Colorado
United States	Aurora St. Luke's Medical Center	Milwaukee	Wisconsin
United States	St. Catherine's Hospital	Munster	Indiana
United States	Naples Community Hospital	Naples	Florida
United States	Advocate Christ Med Center	Oak Lawn	Illinois
United States	St. Anthony's Hospital	Oklahoma City	Oklahoma
United States	Stanford University	Palo Alto	California
United States	St Joseph's Hospital/Barrow Neurological Institute	Phoenix	Arizona
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	St. Mary's Regional Medical Center	Reno	Nevada
United States	St. Louis University Hospital	Saint Louis	Missouri
United States	Multicare Health System	Tacoma	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Accuray Incorporated	University of Pittsburgh

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local progression-free survival, local disease progression, clinical response rate, regional recurrence-free survival, distant recurrence-free survival.		5 years
Secondary	To characterize and compare quality of life before and after stereotactic radiosurgery treatment. To assess procedure-related outcomes after stereotactic radiosurgery of lung tumors.		5 years

External Links

•   Accuray Website